MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jacc.2021.08.052

Медицинская библиотека · Journal of the American College of Cardiology · 2021

Safety and Effectiveness of Paclitaxel Drug-Coated Devices in Peripheral Artery Revascularization: Insights From VOYAGER PAD.

Hess Connie N, Patel Manesh R, Bauersachs Rupert M, Anand Sonia S, Debus E Sebastian, Nehler Mark R, Fanelli Fabrizio, Yeh Robert W, Secemsky Eric A, Beckman Joshua A, Mauri Laura, Govsyeyev Nicholas, Capell Warren H, Brackin Taylor, Berkowitz Scott D, Muehlhofer Eva, Haskell Lloyd P, Hiatt William R, Bonaca Marc P

СтатьяМногоцентровое исследованиеРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

Paclitaxel drug-coated devices (DCDs) were developed to improve lower extremity revascularization (LER) patency in peripheral artery disease (PAD) but have been associated with long-term mortality.

OBJECTIVES

This study assessed DCD safety and effectiveness in LER for PAD.

METHODS

VOYAGER PAD (Vascular Outcomes Study of ASA [acetylsalicylic acid] Along with Rivaroxaban in Endovascular or Surgical Limb Revascularization for PAD) randomized patients with PAD who underwent LER to rivaroxaban or placebo. The primary VOYAGER PAD study efficacy and safety outcomes were composite cardiovascular and limb events and Thrombolysis In Myocardial Infarction major bleeding. For prespecified DCD analyses, primary safety and effectiveness outcomes were mortality and unplanned index limb revascularization (UILR). Major adverse limb events (MALE) were a secondary outcome. Inverse probability treatment weighting was used to account for each subject's propensity for DCD treatment. Effects of rivaroxaban were assessed with Cox proportional hazards models.

RESULTS

Among 4,316 patients who underwent LER, 3,478 (80.6%) were treated for claudication, and 1,342 (31.1%) received DCDs. Median follow-up was 31 months, vital status was ascertained in 99.6% of patients, and there were 394 deaths. After weighting, DCDs were not associated with mortality (HR: 0.95; 95% CI: 0.83-1.09) or MALE (HR: 1.08; 95% CI: 0.90-1.30) but were associated with reduced UILR (3-year Kaplan-Meier: 21.5% vs 24.6%; HR: 0.84; 95% CI: 0.76-0.92). Irrespective of DCD use, consistent benefit of rivaroxaban for composite cardiovascular and limb events (Pinteraction = 0.88) and safety of rivaroxaban with respect to bleeding (Pinteraction = 0.57) were observed.

CONCLUSIONS

In >4,000 patients with PAD who underwent LER, DCDs were not associated with mortality or MALE but were associated with persistent reduction in UILR. These findings provide insight into the safety and effectiveness of DCDs in PAD. (Vascular Outcomes Study of ASA [acetylsalicylic acid] Along with Rivaroxaban in Endovascular or Surgical Limb Revascularization for PAD [VOYAGER PAD]; NCT02504216).

Для цитирования: Hess Connie N, Patel Manesh R, Bauersachs Rupert M, Anand Sonia S, Debus E Sebastian, Nehler Mark R, Fanelli Fabrizio, Yeh Robert W, Secemsky Eric A, Beckman Joshua A, Mauri Laura, Govsyeyev Nicholas, Capell Warren H, Brackin Taylor, Berkowitz Scott D, Muehlhofer Eva, Haskell Lloyd P, Hiatt William R, Bonaca Marc P. Safety and Effectiveness of Paclitaxel Drug-Coated Devices in Peripheral Artery Revascularization: Insights From VOYAGER PAD.. Journal of the American College of Cardiology. 2021. DOI: 10.1016/j.jacc.2021.08.052.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.